-
Nucleophosmin (Acute Myeloid Leukemia Marker)(rNPM1/1901), CF647 conjugate, 0.1mg/mL Price range: 318 CAD through 882 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
Nucleophosmin (Acute Myeloid Leukemia Marker)(rNPM1/1901), CF740 conjugate, 0.1mg/mL Price range: 328 CAD through 896 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
NuMA(A73-B/D12), 0.2mg/mL Price range: 373 CAD through 803 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
NuMA(A73-B/D12), 1mg/mL 656 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
Occludin (Marker of Early Blood Brain Barrier Damage)(OCLN/2181), 0.2mg/mL Price range: 373 CAD through 803 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
Occludin (Marker of Early Blood Brain Barrier Damage)(OCLN/2181), 1mg/mL 656 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
Occludin (Marker of Early Blood Brain Barrier Damage)(OCLN/2181), Biotin conjugate, 0.1mg/mL Price range: 318 CAD through 882 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
Occludin (Marker of Early Blood Brain Barrier Damage)(OCLN/2181), CF405S conjugate, 0.1mg/mL Price range: 318 CAD through 882 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
Occludin (Marker of Early Blood Brain Barrier Damage)(OCLN/2181), CF488A conjugate, 0.1mg/mL Price range: 318 CAD through 882 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
-
Occludin (Marker of Early Blood Brain Barrier Damage)(OCLN/2181), CF568 conjugate, 0.1mg/mL Price range: 318 CAD through 882 CADFor Research Use Only. Not for human or animal consumption, therapeutic, or diagnostic use.
Proudly representing
150+ years of combined research-supply heritage
